These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 8785365

  • 21. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
    Kageyama S, Anderson BD, Hoesterey BL, Hayashi H, Kiso Y, Flora KP, Mitsuya H.
    Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
    Mimoto T, Terashima K, Nojima S, Takaku H, Nakayama M, Shintani M, Yamaoka T, Hayashi H.
    Bioorg Med Chem; 2004 Jan 02; 12(1):281-93. PubMed ID: 14697794
    [Abstract] [Full Text] [Related]

  • 24. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography.
    Adachi M, Ohhara T, Kurihara K, Tamada T, Honjo E, Okazaki N, Arai S, Shoyama Y, Kimura K, Matsumura H, Sugiyama S, Adachi H, Takano K, Mori Y, Hidaka K, Kimura T, Hayashi Y, Kiso Y, Kuroki R.
    Proc Natl Acad Sci U S A; 2009 Mar 24; 106(12):4641-6. PubMed ID: 19273847
    [Abstract] [Full Text] [Related]

  • 25. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K, Kimura T, Abdel-Rahman HM, Nguyen JT, McDaniel KF, Kohlbrenner WE, Molla A, Adachi M, Tamada T, Kuroki R, Katsuki N, Tanaka Y, Matsumoto H, Wang J, Hayashi Y, Kempf DJ, Kiso Y.
    J Med Chem; 2009 Dec 10; 52(23):7604-17. PubMed ID: 19954246
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
    Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ, Kaufman JD, Kiso Y, Torchia DA.
    Biochemistry; 1996 Aug 06; 35(31):9945-50. PubMed ID: 8756455
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S, Hidaka K, Ami E, Nakahara K, Sato A, Nguyen JT, Hamada Y, Hori Y, Ohnishi N, Nagai A, Kimura T, Hayashi Y, Kiso Y.
    J Med Chem; 2008 May 22; 51(10):2992-3004. PubMed ID: 18426195
    [Abstract] [Full Text] [Related]

  • 32. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J, Dohnálek J, Skálová T, Petroková H, Vondrácková E, Hradílek M, Konvalinka J, Soucek M, Brynda J, Fábry M, Sedlácek J, Hasek J.
    Acta Crystallogr D Biol Crystallogr; 2006 May 22; 62(Pt 5):489-97. PubMed ID: 16627941
    [Abstract] [Full Text] [Related]

  • 33. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD, Mak CC, Lin YC, Elder JH, Wong CH.
    Bioorg Med Chem; 2001 May 22; 9(5):1185-95. PubMed ID: 11377177
    [Abstract] [Full Text] [Related]

  • 34. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK, Chapsal BD, Weber IT, Mitsuya H.
    Acc Chem Res; 2008 Jan 22; 41(1):78-86. PubMed ID: 17722874
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
    Thanki N, Rao JK, Foundling SI, Howe WJ, Moon JB, Hui JO, Tomasselli AG, Heinrikson RL, Thaisrivongs S, Wlodawer A.
    Protein Sci; 1992 Aug 22; 1(8):1061-72. PubMed ID: 1304383
    [Abstract] [Full Text] [Related]

  • 37. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.
    Davis DA, Read-Connole E, Pearson K, Fales HM, Newcomb FM, Moskovitz J, Yarchoan R.
    Antimicrob Agents Chemother; 2002 Feb 22; 46(2):402-8. PubMed ID: 11796349
    [Abstract] [Full Text] [Related]

  • 38. HIV protease inhibitors: peptidomimetic drugs and future perspectives.
    Abdel-Rahman HM, Al-karamany GS, El-Koussi NA, Youssef AF, Kiso Y.
    Curr Med Chem; 2002 Nov 22; 9(21):1905-22. PubMed ID: 12369875
    [Abstract] [Full Text] [Related]

  • 39. KNI-272, a highly selective and potent peptidic HIV protease inhibitor.
    Doi M, Ishida T, Katsuya Y, Sasaki M, Taniguchi T, Hasegawa H, Mimoto T, Kiso Y.
    Acta Crystallogr C; 2001 Nov 22; 57(Pt 11):1333-5. PubMed ID: 11706266
    [Abstract] [Full Text] [Related]

  • 40. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.
    Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H.
    Proc Natl Acad Sci U S A; 1999 Jul 20; 96(15):8675-80. PubMed ID: 10411934
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.